表紙：T細胞療法の市場規模、シェア、動向分析レポートモダリティ別、治療法別（CAR T細胞、腫瘍浸潤リンパ球）、適応症別（血液悪性腫瘍（リンパ腫））、セグメント別予測、2023～2030年

市場調査レポート

商品コード

1233261

T細胞療法の市場規模、シェア、動向分析レポートモダリティ別、治療法別（CAR T細胞、腫瘍浸潤リンパ球）、適応症別（血液悪性腫瘍（リンパ腫））、セグメント別予測、2023～2030年

T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030

出版日: 2023年02月28日 | 発行: Grand View Research

| ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

Unprintable PDF (Single User License)

USD 5,950 934,983円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストはできません。PDFの印刷もできません。

Printable PDF (5-User License)

USD 6,950 1,092,123円

レポートPDFを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

Printable PDF (Enterprise License)

USD 8,950 1,406,403円

レポートPDFの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

T細胞療法市場の成長と動向

Grand View Research, Inc.の新しいレポートによると、世界のT細胞療法市場規模は2030年までに308億3000万米ドルに達し、2023年から2030年にかけて17.6%のCAGRを記録すると予測されています。

KymriahとYescartaの画期的な承認が、市場の進展を後押ししています。このような治療法の発売により、この分野の技術革新のためのキャッシュフローが強化され、市場の成長がもたらされました。

第一選択の幹細胞移植や化学療法からキメラ抗原受容体（CAR）T細胞療法へと患者の嗜好が変化していることは、市場成長の機会をもたらすと期待されています。一方、T細胞療法が試験対象とする疾患は絶えず増加しています。他の分野への投資が増加する中、腫瘍性疾患は大きな関心の的となっています。

多発性骨髄腫の有病率の上昇、白血病やリンパ腫の罹患率の上昇は、CAR-T細胞療法の高い採用をもたらし、市場の成長を後押ししています。白血病リンパ腫協会（LLS）によると、米国では20歳以上の小児および青年のうち、約54,000人がリンパ腫、白血病、骨髄腫、骨髄異形成症候群（MDS）を患っていると推定されています。また、2021年には米国で約1,898,160人のがん患者が新たに診断され、そのうち白血病、リンパ腫、骨髄腫の新規発症率は9.8％になると同資料は述べています。

新しい治療法の発売とともに、臨床試験活動の増加が、今後数年間の市場成長を後押しすると予想されます。例えば、2021年12月、ノバルティスは次世代CAR-TプラットフォームであるT-ChargeTMを発売すると宣言し、これは同社のパイプラインにおける多数の新規治験用CAR-T細胞療法の基礎となります。このプラットフォームで作成された最初のノバルティスCAR-T細胞治療薬であるYTB323（抗CD19）とPHE885（抗BCMA）は、第63回米国血液学会年次総会・博覧会（ASH）2021においてノバルティスから発表されました。

非血液性悪性腫瘍に対するCAR T治療法の開発は、抗原の懸念とそれに伴う毒性の問題によって著しく妨げられてきました。この困難を克服し、脳腫瘍やメラノーマなどの適応症におけるT細胞治療の利用を増やすために、主要企業はこの分野の調査にデータ駆動型のアプローチを活用しています。

T細胞治療市場レポートハイライト

モダリティ別では、臨床試験中のT細胞療法製品の数が多いことから、研究ベースのT細胞療法市場が大きなシェアを占めると予想されます。
商業化されたT細胞療法は、規制当局からの製品承認数の増加により、今後数年間で大きな市場シェアを示すと予想されます。
製品タイプ別では、CAR-T療法製品の臨床試験の増加により、2022年にCAR-T細胞療法がセグメントを支配しました。さらに、さまざまながんに対するこれらの治療法の使用の増加が、セグメントの成長を促進すると予想されます。
血液学的悪性腫瘍は、2022年の適応症セグメントを支配しました。リンパ腫と急性リンパ性白血病（ALL）を治療するために、CAR T細胞療法の最も一般的な標的はB細胞上のCD19であり、これが5種類のCAR T療法の承認につながっています。
世界市場全体では、北米が圧倒的なシェアを占めています。この地域の成長は、臨床試験の増加、強力な研究、規制当局の承認の増加により、これらの治療法の導入が増加したことに起因しています。

第1章調査手法

情報調達
情報またはデータ分析
市場の策定と検証

第2章エグゼクティブサマリー

競合環境
市場のスナップショット
セグメントの見通し

第3章市場変数、動向、および範囲

治療タイプの浸透と成長の見通しマッピング、2020
T細胞療法-市場力学
- 市場促進要因分析
  - 疾患治療の養子 T細胞移植アプローチへの投資の増加
  - 市場関係者間の競合の激化
  - さまざまな国でのキムリアとイエスカルタの承認
  - 固形がんに対するCAR-T細胞療法の発展
  - 製造工程における技術の進歩
- 市場抑制要因分析
  - 遺伝子治療に関連する規制、科学、および倫理上の課題
  - 高額な治療費
  - CAR Tの制限事項
- 機会分析
  - 細胞・遺伝子治療施設の拡充
  - 遺伝子および細胞治療分野における世界の資金調達の増加
  - ウイルスおよび非ウイルスベクター製造分野における進行中の開発
規制状況
- 現在および潜在的な将来の承認
- リスク軽減と安全監視のためのフレームワーク
- 地域の規制の枠組み
  - 米国
  - 欧州
  - 中国
  - 日本
養子細胞療法（ACT）の価格設定と支払いモデル
- 保険適用範囲
- 価値ベースの価格ベンチマーク
- 代替支払い戦略
特許情勢
取引、資金調達、パートナーシップ、コラボレーション
- ライセンシング契約
- 合併と買収の取引
- コラボレーションとパートナーシップ
パイプライン分析
- 治験情勢
企業の地理的マッピング
CD19指向のCART療法およびその他のT細胞療法の競合情勢
T細胞療法市場-要因別のSWOT分析（政治と法律、経済、技術）
- 政治情勢
- 経済情勢
- 社会情勢
- テクノロジー情勢
業界分析- ポーターズ
- サプライヤーの交渉力
- 買い手の交渉力
- 代替の脅威
- 新規参入者からの脅威
- 競争企業間の敵対関係

第4章 T細胞療法市場：モダリティ推定・動向分析

T細胞療法市場：モダリティ変動分析
研究
商品

第5章 T細胞療法市場の分類：治療タイプの推定・動向分析

T細胞療法市場：治療タイプの変動分析
CAR T細胞療法
T細胞受容体（TCR）ベース
腫瘍浸潤リンパ球（TIL）ベース

第6章 T細胞療法市場の分類：適応推定・動向分析

T細胞療法市場：適応症の変動分析
血液悪性腫瘍
- リンパ腫
- 白血病
- 骨髄腫
固形腫瘍
- メラノーマ
- 脳と中枢神経系
- 肝臓がん
- その他
その他

第7章 T細胞療法市場の分類：モダリティ、治療タイプ、適応症別の地域推定・動向分析

北米
- SWOT分析
- 米国
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- カナダ
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
欧州
- SWOT分析
- ドイツ
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 英国
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- フランス
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- イタリア
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- スペイン
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
  - スペインのT細胞療法市場推計と予測、2018～2030年（100万米ドル）
- デンマーク
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- スウェーデン
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- ノルウェー
  - 主要な国のダイナミクス
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
アジア太平洋地域
- SWOT分析
  - 主要な地域のダイナミクス
- 日本
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 中国
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- インド
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- 韓国
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- オーストラリア
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- タイ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
ラテンアメリカ
- SWOT分析
- 主な地域のダイナミクス
- ブラジル
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- メキシコ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- アルゼンチン
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
中東およびアフリカ（MEA）
- SWOT分析
- 主な地域のダイナミクス
- 南アフリカ
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- サウジアラビア
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- アラブ首長国連邦
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ
- クウェート
  - 対象疾患の有病率
  - 競合シナリオ
  - 規制の枠組み
  - 償還シナリオ

第8章競合情勢

Strategy Framework
企業プロファイル
- Novartis AG
  - 会社概要
  - エイベックス株式会社
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Gilead Sciences
  - 会社概要
  - カイトファーマ
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- bluebird bio, Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- TCR2 Therapeutics Inc
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Sorrento Therapeutics
  - 会社概要
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Fate Therapeutics
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Merck KGaA
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Pfizer Inc.
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Amgen
  - 会社概要
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ
- Celgene Corporation
  - 会社概要
  - ジュノ・セラピューティクス
  - 財務実績
  - 製品のベンチマーク
  - 戦略的イニシアチブ

図表

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 4 Global T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 5 Global T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 6 Global T-Cell Therapy Market by Region, 2018 - 2030 (USD Million)
Table 7 North America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 8 North America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 9 North America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 10 North America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 11 U.S. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 12 U.S. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 13 U.S. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 14 Canada T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 15 Canada T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 16 Canada T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 17 Europe T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 18 Europe T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 19 Europe T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 20 Europe T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 21 Germany T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 22 Germany T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 23 Germany T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 24 U.K. T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 25 U.K. T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 26 U.K. T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 27 France T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 28 France T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 29 France T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 30 Italy T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 31 Italy T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 32 Italy T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 33 Spain T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 34 Spain T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 35 Spain T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 36 Denmark T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 37 Denmark T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 38 Denmark T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 39 Sweden T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 40 Sweden T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 41 Sweden T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 42 Norway T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 43 Norway T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 44 Norway T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 45 Asia Pacific T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 47 Asia Pacific T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 48 Asia Pacific T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 49 China T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 50 China T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 51 China T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 52 Japan T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 53 Japan T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 54 Japan T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 55 India T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 56 India T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 57 India T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 58 South Korea T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 59 South Korea T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 60 South Korea T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 61 Australia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 62 Australia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 63 Australia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 64 Thailand T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 65 Thailand T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 66 Thailand T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 67 Latin America T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 68 Latin America T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 69 Latin America T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 70 Latin America T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 71 Brazil T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 72 Brazil T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 73 Brazil T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 74 Mexico T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 75 Mexico T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 76 Mexico T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 77 Argentina T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 78 Argentina T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 79 Argentina T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 80 Middle East & Africa T-Cell Therapy Market by Country, 2018 - 2030 (USD Million)
Table 81 Middle East & Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 82 Middle East & Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 84 South Africa T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 85 South Africa T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 86 South Africa T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 88 Saudi Arabia T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 89 Saudi Arabia T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 90 UAE T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 91 UAE T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 92 UAE T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)
Table 93 Kuwait T-Cell Therapy Market by Modality, 2018 - 2030 (USD Million)
Table 94 Kuwait T-Cell Therapy Market by Therapy Type, 2018 - 2030 (USD Million)
Table 95 Kuwait T-Cell Therapy Market by Indication, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 T-Cell Therapy, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 10 Penetration & Growth Prospect Mapping
Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 12 Porter's Five Forces Analysis
Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
Fig. 14 Regional Marketplace: Key Takeaways
Fig. 15 Global T-Cell Therapy Market for Commercialized,2018 - 2030 (USD Million)
Fig. 16 Global T-Cell Therapy Market for Research, 2018 - 2030 (USD Million)
Fig. 17 Global T-Cell Therapy Market for In-Situ Hybridization Diagnostics, 2018 - 2030 (USD Million)
Fig. 18 Global T-Cell Therapy Market for CAR T Cell Therapy, 2018 - 2030 (USD Million)
Fig. 19 Global T-Cell Therapy Market for T Cell Receptor (TCR)-based,2018 - 2030 (USD Million)
Fig. 20 Global T-Cell Therapy Market for Tumor Infiltrating Lymphocytes (TIL)-based, 2018 - 2030 (USD Million)
Fig. 21 Global T-Cell Therapy Market for Hematologic Malignancies,2018 - 2030 (USD Million)
Fig. 22 Global T-Cell Therapy Market for Lymphoma, 2018 - 2030 (USD Million)
Fig. 23 Global T-Cell Therapy Market for Leukemia, 2018 - 2030 (USD Million)
Fig. 24 Global T-Cell Therapy Market for Myeloma, 2018 - 2030 (USD Million)
Fig. 25 Global T-Cell Therapy Market for Solid Tumors, 2018 - 2030 (USD Million)
Fig. 26 Global T-Cell Therapy Market for Melanoma, 2018 - 2030 (USD Million)
Fig. 27 Global T-Cell Therapy Market for Brain and central nervous system, 2018 - 2030 (USD Million)
Fig. 28 Global T-Cell Therapy Market for Liver cancer,2018 - 2030 (USD Million)
Fig. 29 Global T-Cell Therapy Market for Others,2018 - 2030 (USD Million)
Fig. 30 Global T-Cell Therapy Market for Other Indications, 2018 - 2030 (USD Million)
Fig. 31 Regional Outlook, 2021 & 2030
Fig. 32 North America T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 33 U.S. T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 34 Canada T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 35 Europe T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 36 Germany T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 37 U.K. T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 38 France T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 39 Italy T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 40 Spain T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 41 Denmark T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 42 Sweden T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 43 Norway T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 44 Asia Pacific T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 45 Japan T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 46 China T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 47 India T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 48 Australia T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 49 South Korea T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 50 Thailand T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 51 Latin America T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 52 Brazil T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 53 Mexico T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 54 Argentina T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 55 Middle East and Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 56 South Africa T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 57 Saudi Arabia T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 58 UAE T-Cell Therapy Market 2018 - 2030 (USD Million)
Fig. 59 Kuwait T-Cell Therapy Market 2018 - 2030 (USD Million)

Product Code: GVR-3-68038-685-1

T-cell Therapy Market Growth & Trends:

The global T-cell therapy market size is expected to reach USD 30.83 billion by 2030 and is expected to register a CAGR of 17.6% from 2023 to 2030 according to a new report by Grand View Research, Inc. The landmark approval of Kymriah and Yescarta have boosted advancements in the market. The launch of such therapies has strenghtned cash flow for innovation in this area resulting in market growth.

The shifting patients' preference from first-line stem cell transplant and chemotherapy towards chimeric antigen receptor (CAR) T cell therapy is expected to create growth opportunities for the market growth. On the other hand, the number of diseases that T-cell therapies are being tested on is constantly growing. With increasing investments in other areas, oncological illnesses are the focus of significant interest.

Rise in the prevalence of multiple myeloma and the rise in incidences of leukemia and lymphomia resulted in high adoption of CAR-T cell therapy, which boosts market growth. According to the Leukemia & Lymphoma Society (LLS), estimated around 54,000 children and adolescents above 20 years in the U.S. have lymphoma, leukaemia, myeloma,and myelodysplastic syndromes (MDS). Moreover, the same source stated that around 1,898,160 new cancer cases will be diagnosed in the U.S. in 2021, with new instances of leukaemia, lymphoma, and myeloma likely to represent 9.8% of those cases.

An increase in clinical trial activity along with new therapy launches is expected to boost the market growth in the coming years. For instance, in December 2021, Novartis declared to launch T-ChargeTM, its next-generation CAR-T platform, which will be the basis for a number of novel investigational CAR-T cell therapies in the company's pipeline. The first Novartis CAR-T cell treatments created with this platform, YTB323 (anti-CD19) and PHE885 (anti-BCMA), were presented by Novartis at the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021.

The development of CAR T treatments for non-hematological malignancies has been significantly hampered by the antigen concerns and associated toxicity issues. To overcome the difficulty and increase the use of T-cell treatment in indication types such as brain cancer and melanoma, key players are utilising a data-driven approach to research this area.

T-cell Theraphy Market Report Highlights:

By Modality, the research-based market for T-cell therapies is expected to occupy the larger share of market space due to high number of T-cell therapy products under clinical trials.

Commercialized T-cell therapies are expected to show significant market share in the coming years owing to the increase in the number of product approval from the regulatory body.

By therapy type, CAR-T cell therapy dominated the segment in 2022 owing to the increase in clinical trials for CAR-T therapy products. Moreover, an increase in the usage of these therapies in different cancer is expected to boost segment growth.

Haematological malignancies dominated the indication segment in 2022. In order to treat lymphoma and acute lymphocytic leukaemia (ALL), the most common target of CAR T-cell therapies is CD19 on B-cells, which has led to the approval of five different CAR T therapies.

North America dominated the overall global market. The regional growth is attributed to the increasing clinical trials, strong research, and increasing regulatory approval, resulting increase in the uptake of these therapies.

Table of contents

Chapter 1 Research Methodology

1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Market Formulation & Validation

Chapter 2 Executive Summary

2.1 Competition Milieu
2.2 Market Snapshot
2.3 Segment Outlook

Chapter 3 Market Variables, Trends, & Scope

3.1 Penetration & Growth Prospect Mapping for Therapy Type, 2020
3.2 T-Cell Therapy - Market Dynamics
- 3.2.1 Market driver analysis
  - 3.2.1.1 Rising investment in adoptive T cell transfer approaches of disease treatment
  - 3.2.1.2 Growing competition among market players
  - 3.2.1.3 Approval of Kymriah and Yescarta across various countries
  - 3.2.1.4 Developments in CAR T-cell therapy for solid tumors
  - 3.2.1.5 Technological advancements in manufacturing process
- 3.2.2 Market restraint analysis
  - 3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
  - 3.2.2.1 High prices of therapies
  - 3.2.2.2 CAR T limitations
- 3.2.3 Opportunity analysis
  - 3.2.3.1 Facility expansion for cell and gene therapies
  - 3.2.3.1 Rising global financings in gene and cell therapy arena
  - 3.2.3.2 Ongoing developments in viral & non-viral vector manufacturing arena
3.3 Regulatory Landscape
- 3.3.1 Current and potential future approvals
- 3.3.2 Frameworks for risk mitigation and safety monitoring
- 3.3.3 Regulatory framework, by geography
  - 3.3.3.1 U.S.
  - 3.3.3.2 Europe
  - 3.3.3.3 China
  - 3.3.3.4 Japan
3.4 Pricing and Payment Models for Adoptive Cellular Therapies (ACT)
- 3.4.1 Insurance coverage
- 3.4.2 Value-based price benchmarks
- 3.4.3 Alternate payment strategies
3.5 Patent Landscape
3.6 Deals, Funding's, Partnerships and Collaborations
- 3.6.1 Licensing deals
- 3.6.2 Merger & acquisition deals
- 3.6.3 Collaboration & partnerships
3.7 Pipeline Analysis
- 3.7.1 Clinical trial landscape
3.8 Geographic Mapping of Companies
3.9 Competitive Landscape for CD19directed CART Therapies and Other T-cell therapies
3.10 T-cell Therapy Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
- 3.10.1 Political landscape
- 3.10.2 Economic landscape
- 3.10.3 Social landscape
- 3.10.4 Technology landscape
3.11 Industry Analysis - Porter's
- 3.11.1 Supplier bargaining power
- 3.11.2 Buyer bargaining power
- 3.11.3 Substitution threat
- 3.11.4 Threat from new entrant
- 3.11.5 Competitive rivalry

Chapter 4 T-cell Therapy Market: Modality Estimates & Trend Analysis

4.1 T-cell Therapy Market: Modality Movement Analysis
4.2 Research
- 4.2.1 Global research-based T-cell therapy market, 2018 - 2030 (USD Million)
4.3 Commercialized
- 4.3.1 Global commercial T-cell therapy market, 2018 - 2030 (USD Million)

Chapter 5 T-cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis

5.1 T-cell Therapy Market: Therapy Type Movement Analysis
5.2 CAR T-cell Therapy
- 5.2.1 Global CAR T-cell Therapy market, 2018 - 2030 (USD Million)
5.3 T Cell Receptor (TCR)-based
- 5.3.1 Global T Cell Receptor (TCR)-based therapy market, 2018 - 2030 (USD Million)
5.4 Tumor Infiltrating Lymphocytes (TIL)-based
- 5.4.1 Global Tumor Infiltrating Lymphocytes (TIL)-based therapy market, 2018 - 2030 (USD Million)

Chapter 6 T-cell Therapy Market Categorization: Indication Estimates & Trend Analysis

6.1 T-cell Therapy Market: Indication Movement Analysis
6.2 Hematologic Malignancies
- 6.2.1 Global T-cell therapy market for hematologic malignancies, 2018 - 2030 (USD Million)
- 6.2.2 Lymphoma
  - 6.2.2.1 Global T-cell therapy market for lymphoma, 2018 - 2030 (USD Million)
- 6.2.3 Leukemia
  - 6.2.3.1 Global T-cell therapy market for leukemia, 2018 - 2030 (USD Million)
- 6.2.4 Myeloma
  - 6.2.4.1 Global T-cell therapy market for myeloma, 2018 - 2030 (USD Million)
6.3 Solid Tumors
- 6.3.1 Global T-cell therapy market for solid tumors, 2018 - 2030 (USD Million)
- 6.3.2 Melanoma
  - 6.3.2.1 Global T-cell therapy market for melanoma, 2018 - 2030 (USD Million)
- 6.3.3 Brain & Central Nervous System
  - 6.3.3.1 Global T-cell therapy market for brain & central nervous system, 2018 - 2030 (USD Million)
- 6.3.4 Liver cancer
  - 6.3.4.1 Global T-cell therapy market for liver cancer, 2018 - 2030 (USD Million)
- 6.3.5 Others
  - 6.3.5.1 Global T-cell therapy market for other cancer forms, 2018 - 2030 (USD Million)
6.4 Others
- 6.4.1 Global T-cell therapy market for others, 2018 - 2030 (USD Million)

Chapter 7 T-cell Therapy Market Categorization: Regional Estimates & Trend Analysis, by Modality, Therapy Type & Indication

7.1 North America
- 7.1.1 SWOT Analysis
  - 7.1.1.1 North America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.1.2 U.S.
  - 7.1.2.1 Key country dynamics
  - 7.1.2.2 Target disease prevalence
  - 7.1.2.3 Competitive scenario
  - 7.1.2.4 Regulatory framework
  - 7.1.2.5 Reimbursement scenario
  - 7.1.2.6 U.S. T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.1.3 Canada
  - 7.1.3.1 Key country dynamics
  - 7.1.3.2 Target disease prevalence
  - 7.1.3.3 Competitive scenario
  - 7.1.3.4 Regulatory framework
  - 7.1.3.5 Reimbursement scenario
  - 7.1.3.6 Canada T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
7.2 Europe
- 7.2.1 SWOT Analysis
  - 7.2.1.1 Europe T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.2 Germany
  - 7.2.2.1 Key country dynamics
  - 7.2.2.2 Target disease prevalence
  - 7.2.2.3 Competitive scenario
  - 7.2.2.4 Regulatory framework
  - 7.2.2.5 Reimbursement scenario
  - 7.2.2.6 Germany T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.3 UK
  - 7.2.3.1 Key country dynamics
  - 7.2.3.2 Target disease prevalence
  - 7.2.3.3 Competitive scenario
  - 7.2.3.4 Regulatory framework
  - 7.2.3.5 Reimbursement scenario
  - 7.2.3.6 UK T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.4 France
  - 7.2.4.1 Key country dynamics
  - 7.2.4.2 Target disease prevalence
  - 7.2.4.3 Competitive scenario
  - 7.2.4.4 Regulatory framework
  - 7.2.4.5 Reimbursement scenario
  - 7.2.4.6 France T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.5 Italy
  - 7.2.5.1 Key country dynamics
  - 7.2.5.2 Target disease prevalence
  - 7.2.5.3 Competitive scenario
  - 7.2.5.4 Regulatory framework
  - 7.2.5.5 Reimbursement scenario
  - 7.2.5.6 Italy T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.6 Spain
  - 7.2.6.1 Key country dynamics
  - 7.2.6.2 Target disease prevalence
  - 7.2.6.3 Competitive scenario
  - 7.2.6.4 Regulatory framework
  - 7.2.6.5 Reimbursement scenario
  - 7.2.6.6 Spain T-cell therapy market estimates and f.orecasts, 2018 - 2030 (USD Million)
- 7.2.7 Denmark
  - 7.2.7.1 Key country dynamics
  - 7.2.7.2 Target disease prevalence
  - 7.2.7.3 Competitive scenario
  - 7.2.7.4 Regulatory framework
  - 7.2.7.5 Reimbursement scenario
  - 7.2.7.6 Denmark T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.8 Sweden
  - 7.2.8.1 Key country dynamics
  - 7.2.8.2 Target disease prevalence
  - 7.2.8.3 Competitive scenario
  - 7.2.8.4 Regulatory framework
  - 7.2.8.5 Reimbursement scenario
  - 7.2.8.6 Sweden T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.9 Norway
  - 7.2.9.1 Key country dynamics
  - 7.2.9.2 Target disease prevalence
  - 7.2.9.3 Competitive scenario
  - 7.2.9.4 Regulatory framework
  - 7.2.9.5 Reimbursement scenario
  - 7.2.9.6 Norway T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.2.10 Rest Of Europe T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.3 Asia Pacific
- 7.3.1 SWOT analysis
  - 7.3.1.1 Key Region Dynamics
  - 7.3.1.2 Asia Pacific T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.2 Japan
  - 7.3.2.1 Target disease prevalence
  - 7.3.2.2 Competitive scenario
  - 7.3.2.3 Regulatory framework
  - 7.3.2.4 Reimbursement scenario
  - 7.3.2.5 Japan T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.3 China
  - 7.3.3.1 Target disease prevalence
  - 7.3.3.2 Competitive scenario
  - 7.3.3.3 Regulatory framework
  - 7.3.3.4 Reimbursement scenario
  - 7.3.3.5 China T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.4 India
  - 7.3.4.1 Target disease prevalence
  - 7.3.4.2 Competitive scenario
  - 7.3.4.3 Regulatory framework
  - 7.3.4.4 Reimbursement scenario
  - 7.3.4.5 India T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.5 South Korea
  - 7.3.5.1 Target disease prevalence
  - 7.3.5.2 Competitive scenario
  - 7.3.5.3 Regulatory framework
  - 7.3.5.4 Reimbursement scenario
  - 7.3.5.5 South Korea T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.6 Australia
  - 7.3.6.1 Target disease prevalence
  - 7.3.6.2 Competitive scenario
  - 7.3.6.3 Regulatory framework
  - 7.3.6.4 Reimbursement scenario
  - 7.3.6.5 Austrlia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.7 Thailand
  - 7.3.7.1 Target disease prevalence
  - 7.3.7.2 Competitive scenario
  - 7.3.7.3 Regulatory framework
  - 7.3.7.4 Reimbursement scenario
  - 7.3.7.5 Thailand T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.3.8 Rest Of Asia Pacific T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.4 Latin America
- 7.4.1 SWOT Analysis
- 7.4.2 Key Regional Dynamics
  - 7.4.2.1 Latin America T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.3 Brazil
  - 7.4.3.1 Target disease prevalence
  - 7.4.3.2 Competitive scenario
  - 7.4.3.3 Regulatory framework
  - 7.4.3.4 Reimbursement scenario
  - 7.4.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.4 Mexico
  - 7.4.4.1 Target disease prevalence
  - 7.4.4.2 Competitive scenario
  - 7.4.4.3 Regulatory framework
  - 7.4.4.4 Reimbursement scenario
  - 7.4.4.5 Mexico T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.5 Argentina
  - 7.4.5.1 Target disease prevalence
  - 7.4.5.2 Competitive scenario
  - 7.4.5.3 Regulatory framework
  - 7.4.5.4 Reimbursement scenario
  - 7.4.5.5 Argentina T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.4.6 Rest Of Latam T-Cell Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5 Middle East & Africa (MEA)
- 7.5.1 SWOT Analysis
- 7.5.2 KEY regional Dynamics
  - 7.5.2.1 Middle East & Africa T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.3 South Africa
  - 7.5.3.1 Target disease prevalence
  - 7.5.3.2 Competitive scenario
  - 7.5.3.3 Regulatory framework
  - 7.5.3.4 Reimbursement scenario
  - 7.5.3.5 Brazil T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.4 Saudi Arabia
  - 7.5.4.1 Target disease prevalence
  - 7.5.4.2 Competitive scenario
  - 7.5.4.3 Regulatory framework
  - 7.5.4.4 Reimbursement scenario
  - 7.5.4.5 Saudi Arabia T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.5 UAE
  - 7.5.5.1 Target disease prevalence
  - 7.5.5.2 Competitive scenario
  - 7.5.5.3 Regulatory framework
  - 7.5.5.4 Reimbursement scenario
  - 7.5.5.5 UAE T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.6 Kuwait
  - 7.5.6.1 Target disease prevalence
  - 7.5.6.2 Competitive scenario
  - 7.5.6.3 Regulatory framework
  - 7.5.6.4 Reimbursement scenario
  - 7.5.6.5 Kuwait T-cell therapy market estimates and forecasts, 2018 - 2030 (USD Million)
- 7.5.7 Rest of MEA T-cell therapy market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

8.1 Strategy Framework
8.2 Company Profiles
- 8.2.1 Novartis AG
  - 8.2.1.1 Company overview
  - 8.2.1.1.1 AveXis, Inc.
  - 8.2.1.2 Financial performance
  - 8.2.1.3 Product benchmarking
  - 8.2.1.4 Strategic initiatives
- 8.2.2 Gilead Sciences
  - 8.2.2.1 Company overview
  - 8.2.1.1.1 Kite Pharma
  - 8.2.2.2 Financial performance
  - 8.2.2.3 Product benchmarking
  - 8.2.2.4 Strategic initiatives
- 8.2.3 bluebird bio, Inc.
  - 8.2.3.1 Company overview
  - 8.2.3.2 Financial performance
  - 8.2.3.3 Product benchmarking
  - 8.2.3.4 Strategic initiatives
- 8.2.4 TCR2 Therapeutics Inc
  - 8.2.4.1 Company overview
  - 8.2.4.2 Financial performance
  - 8.2.4.3 Product benchmarking
  - 8.2.4.4 Strategic initiatives
- 8.2.5 Sorrento Therapeutics
  - 8.2.5.1 Company overview
  - 8.2.5.2 Product benchmarking
  - 8.2.5.3 Strategic initiatives
- 8.2.6 Fate Therapeutics
  - 8.2.6.1 Company overview
  - 8.2.6.2 Financial performance
  - 8.2.6.3 Product benchmarking
  - 8.2.6.3 Strategic initiatives
- 8.2.7 Merck KGaA
  - 8.2.7.1 Company overview
  - 8.2.7.2 Financial performance
  - 8.2.7.3 Product benchmarking
  - 8.2.7.3 Strategic initiatives
- 8.2.8 Pfizer Inc.
  - 8.2.8.1 Company overview
  - 8.2.8.2 Financial performance
  - 8.2.8.3 Product benchmarking
  - 8.2.8.4 Strategic initiatives
- 8.2.9 Amgen
  - 8.2.9.1 Company overview
  - 8.2.9.2 Financial performance
  - 8.2.9.3 Product benchmarking
  - 8.2.9.4 Strategic initiatives
- 8.2.10 Celgene Corporation
  - 8.2.10.1 Company overview
  - 8.2.10.1.1 Juno Therapeutics
  - 8.2.10.2 Financial performance
  - 8.2.10.3 Product benchmarking
  - 8.2.10.4 Strategic initiatives